Arax Advisory Partners’s Integra LifeSciences IART Stock Holding History

Arax Advisory Partners’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$265K	Buy	14,779 +13,082	+771%	+$183K	﹤0.01%	2050
2026 Q1	$16K	Sell	1,697 -14,026	-89%	-$154K	﹤0.01%	2214
2025 Q4	$195K	Sell	15,723 -23,668	-60%	-$315K	0.01%	1056
2025 Q3	$564K	Buy	39,391 +39,064	+11,946%	+$535K	0.01%	862
2025 Q2	$4.01K	Buy	327 +294	+891%	+$4.27K	﹤0.01%	2324
2025 Q1	$726	Buy	+33	New	+$776	﹤0.01%	2427
2024 Q4	–	Sell	-873	Closed	-$15.9K	–	2567
2024 Q3	$15.9K	Sell	873 -11	-1%	-$255	﹤0.01%	1181
2024 Q2	$25.8K	Buy	884 +867	+5,100%	+$25.7K	﹤0.01%	892
2024 Q1	$603	Hold	17	–	–	﹤0.01%	1220
2023 Q4	$741	Hold	17	–	–	﹤0.01%	1175
2023 Q3	$650	Hold	17	–	–	﹤0.01%	1206
2023 Q2	$700	Sell	17 -1	-6%	-$48	﹤0.01%	1163
2023 Q1	$1.03K	Hold	18	–	–	﹤0.01%	1094
2022 Q4	$1.01K	Hold	18	–	–	﹤0.01%	1072
2022 Q3	$1K	Hold	18	–	–	﹤0.01%	1091
2022 Q2	$1K	Hold	18	–	–	﹤0.01%	1059
2022 Q1	$1K	Sell	18 -1	-5%	-$66	﹤0.01%	1044
2021 Q4	$1K	Buy	+19	New	+$1.28K	﹤0.01%	1025

Other funds holding IART

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Arax Advisory Partners's IART Position: Q2 2026 in Review

Arax Advisory Partners increased its Integra LifeSciences (IART) stake by 771% in Q2 2026, buying an estimated $183K and bringing the position to 14,779 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #2050.

Arax Advisory Partners first reported a position in IART in Q4 2021 and has held it in 18 quarters since. The position peaked at $564K in Q3 2025. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.

Arax Advisory Partners held 14,779 shares of Integra LifeSciences worth $265K as of Q2 2026.
Arax Advisory Partners bought 13,082 Integra LifeSciences shares in Q2 2026, an estimated $183K.
Integra LifeSciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2050 holding.
Arax Advisory Partners first reported a position in Integra LifeSciences in Q4 2021 and has held it in 18 quarters since.
Arax Advisory Partners's Integra LifeSciences position peaked at $564K in Q3 2025.
212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.